Jason Pitofsky, Senior Vice President and Controller at Regeneron Pharmaceuticals, Inc., has reported multiple stock transactions that occurred on November 4, 2026. These transactions included both acquisitions and disposals of common stock, which may have implications for his ownership stake in the company.

According to the recent SEC filing (accession number 0002009236-26-000003), Pitofsky acquired a total of 3,883 shares of Regeneron stock at prices ranging from $492.00 to $726.53 per share. In addition, he disposed of 2,394 shares at prices between $939.57 and $950.76 per share. Following these transactions, Pitofsky's total ownership in Regeneron stands at 4,272 shares.

Regeneron Pharmaceuticals, based in Tarrytown, New York, is a prominent player in the pharmaceutical preparations sector. The company is known for its innovative treatments and therapies, particularly in the fields of ophthalmology, oncology, and immunology. As a publicly traded entity, Regeneron is listed under the ticker symbol REGN.

The filing indicates that Pitofsky's transactions were executed as part of his role as an officer of the company. Specifically, he is not a director but holds the title of Senior Vice President and Controller, which often involves significant responsibilities in financial oversight and reporting.

These transactions may impact the perception of Regeneron's management strategies, particularly regarding executive compensation and stock option plans. In the pharmaceutical industry, such disclosures are closely monitored by investors and analysts, as they can signal confidence or concerns about the company's future performance.

What remains unclear from the filing is whether there will be any further actions or disclosures related to these transactions. The filing does not specify any upcoming votes or additional filings that may follow this report.